To The Moon

After a bruising three years in the market, $Pfizer(PFE)$ now trades like a company investors have decided to put in the “too hard” pile. Its share price has slid 42% over three years while the S&P 500 has surged, leaving the stock at $25.16 and the dividend yield hovering at an eyebrow-raising 7%. The pandemic vaccine boom is long gone, but Pfizer hasn’t been idling — it’s been retooling its portfolio, cutting debt, and banking on new growth drivers. I think the story here is less about a one-off bounce and more about a patient transformation that could make today’s valuation look surprisingly cheap in hindsight.

From vaccine highs to a steadier prescription for growth

Yield with Backbone

A 7% yield often smells of trouble — it can be the last gasp before a dividend cut. In Pfizer’s case, the numbers suggest otherwise. The annual payout of $1.72 sits well below expected 2025 adjusted earnings per share of roughly $3, giving it a payout ratio under 60% on forward estimates. That cushion has allowed management to keep raising the dividend for 15 consecutive years, even as pandemic revenues evaporated. More quietly, the company has chipped away at its $62 billion debt pile, bringing its debt-to-equity ratio to under 70%. For a business with $15 billion in operating cash flow and $16 billion in free cash flow over the past year, this balance sheet work isn’t just good housekeeping — it’s future-proofing the dividend through the next economic or regulatory squall.

When the yield’s this high, the real question is whether it’s built on bedrock or sand.

Steady dividend growth and a payout ratio that leaves room to breathe (2019–2025).

An insight worth noting: Pfizer’s beta is just 0.44, meaning it tends to swing less than half as much as the market. For income-focused investors, that stability, combined with the yield, offers a relatively rare combination — high income without high volatility.

Shifting the Revenue Engine

The pandemic left Pfizer’s revenue mix distorted, with COVID-19 vaccines and treatments contributing an outsized chunk. That wave has now crashed; COVID-related sales are under $2 billion for the first half of 2025, down sharply from their peak. Rather than mourn the loss, Pfizer has been leaning into areas less exposed to political price pressure and patent cliffs. Oncology sales are up 9% year to date, specialty medicines up 6%, together accounting for $16.5 billion in the first half. These are not minor sidelines — they are becoming the new core.

Pfizer’s revenue engine has been rebuilt while no one was looking.

From COVID highs to a new core in oncology and specialty medicines

That said, oncology is a fiercely competitive field. Niche cancer therapies that appear promising often attract rival programmes from other deep-pocketed pharma giants, squeezing market share and pricing power. The pipeline risk here is real; drug development timelines are long, costs are high, and regulatory approval is never guaranteed.

The patent cliff for Eliquis — worth around $5 billion annually — is perhaps the biggest single overhang. Even with strong growth in oncology and specialty drugs, replacing that revenue fully will require either faster pipeline success or strategic acquisitions. Given Pfizer’s mixed track record with large deals, execution will be critical.

Valuation Meets Sentiment

On paper, $Pfizer(PFE)$ is priced like a sluggish, ex-growth stalwart. The stock trades at just 8.2 times forward earnings and a price-to-sales ratio of 2.2 — a discount to most large-cap pharma peers. Its PEG ratio of 0.84 suggests the market is paying less than a dollar for each dollar of expected earnings growth. For context, analysts project roughly 9% annualised EPS growth over the next three to five years, a rate that, if achieved, would make the current multiple look overly cautious.

However, there may be good reasons for that discount. Pfizer’s R&D productivity has been patchy, and while it’s delivered some successes, its history of blockbuster drug development is mixed compared to top-tier rivals. Large acquisitions — think Wyeth — have sometimes delivered more integration headaches than lasting value. The market could be pricing in this execution risk alongside the usual regulatory overhang.

On regulation, drug pricing pressure is not just a current administration talking point. It’s a bipartisan, structural trend in U.S. healthcare policy. The Medicare negotiation process is already eroding pricing power for some top-selling drugs, and over time, this could compress margins industry-wide regardless of who occupies the White House. That means valuation recovery will likely depend as much on cost discipline and pipeline success as on macro political shifts.

An under-the-radar factor here is short interest, currently just 1.9% of the float. Low short interest suggests the market isn’t actively betting on a collapse, which often makes it easier for sentiment to pivot quickly when fundamentals surprise to the upside.

My Take

Pfizer’s story is no longer about pandemic-era windfalls; it’s about whether a leaner, more focused business can deliver stable income and modest growth in a highly regulated, fiercely competitive environment. The dividend is real, the debt is shrinking, and the growth engines are shifting towards higher-margin, defensible niches. But investors should be clear-eyed: oncology growth is promising but crowded, the Eliquis cliff is steep, and R&D execution will need to improve to justify even a modest rerating.

Patience, dividends, and the slow turning of market sentiment

At 8 times forward earnings, you’re not paying for perfection; you’re buying a slow-moving, cash-rich ship that’s adjusting its sails in choppy waters. I’m not expecting fireworks in the next quarter. But for an investor who values income, a margin of safety on valuation, and the possibility of a sentiment swing, $Pfizer(PFE)$ offers a blend that’s rare in a market trading near all-time highs. The post-pandemic playbook is still being written, and at this entry point, I’m happy to keep a close watch on how the next chapters unfold — with a 7% yield as my bookmark.

@TigerStars @Daily_Discussion @Tiger_comments @Tiger_SG @Tiger_Earnings @TigerClub @TigerWire